Another interesting approach, currently under clinical evaluation, is the generation of leukemia-specific antigen by deleting CD33 from normal hematopoietic stem and progenitor cells, thereby enabling specific targeting of AML with CD33-CAR-T cells, since hematopoietic system would be resistant to CD33-targeted therapy (6). Here, CD33 is linked to leukemia.